23,036,271
Vote Records
25,695
Companies
11,771
Funds
3,902
Managers

Home › Companies › PLIANT THERAPEUTICS INC. › 2023-2024

PLIANT THERAPEUTICS INC. 2023-2024 Proxy Voting Records

Download data (CSV): ballot items · votes by manager · column guide.

Compiled from SEC Form N-PX filings and PLIANT THERAPEUTICS INC.’s Form 8-K, filed June 14, 2024 (Item 5.07 on EDGAR). Page generated November 20, 2026.

  • 5Ballot items
  • 175Asset managers, any item
  • 996Fund votes
  • June 13, 2024Meeting date

Results at a glance

Meeting of June 13, 2024: 5 items on PLIANT THERAPEUTICS INC.’s Form 8-K, filed June 14, 2024: 1 approved · 3 passed (calculated) · 1 failed (calculated).

Dissent

Significant dissent: 1 director (24.6% against); 1 say-on-pay vote (45.3% support).

Dissent tiers, on the company’s own Form 8-K tally (support = FOR ÷ (FOR + AGAINST), or FOR ÷ (FOR + WITHHELD) on a withhold ballot; abstentions and broker non-votes excluded): shareholder proposals with 15% support or more are notable, 25% significant, 40% high; director nominees with 10% or more against or withheld are notable, 20% significant; say-on-pay under 80% support is notable, under 70% significant; equity and compensation plans with 15% or more against are notable, 25% significant; any other item the board put forward with 15% or more against is notable. How this is decided

Proxy season: 2023-2024 2024-2025 2025-2026

Activist investors: Tang Capital (13D, 9.6%, as of March 10, 2025) · BML Capital (13F, 2.5%, as of September 30, 2026)

Explore PLIANT THERAPEUTICS INC. in the interactive database Compare manager voting policies

Official 2023-2024 meeting results reported by PLIANT THERAPEUTICS INC.

These tallies are PLIANT THERAPEUTICS INC.’s own, as disclosed to the U.S. Securities and Exchange Commission on Form 8-K, filed June 14, 2024 (Item 5.07, “Submission of Matters to a Vote of Security Holders”). They cover every share voted at the meeting, not just the funds that file Form N-PX.

PLIANT THERAPEUTICS INC. — official shareholder meeting results, meeting held June 13, 2024
Ballot itemForAgainst AbstainWithheldBroker non-votesSupport (of votes cast)Reported outcomeVoting standard
Elect Director: Hoyoung Huh, M.D., Ph.D. 39,087,800---- 12,731,485-- 75%Passed (calculated)—
Elect Director: Darren Cline, MBA 51,397,449---- 421,836-- 99.2%Passed (calculated)—
Elect Director: David Pyott, MA, MBA 48,388,729---- 3,430,556-- 93%Passed (calculated)—
2. Company's stockholders failed to approve, on a non-binding advisory basis, the compensation of the Company's named executive officers 23,479,35328,329,65510,277 ---- 45.3%Failed (calculated)a majority of the votes cast
3. The selection of Deloitte & Touche LLP as the Company's independent registered public accounting firm 56,628,36810,85362,998 ---- 99.9%Approved—

Source: PLIANT THERAPEUTICS INC., Form 8-K, filed with the SEC on June 14, 2024 — read the filing on EDGAR.

How asset managers voted at the PLIANT THERAPEUTICS INC. 2023-2024 meeting

175 asset managers disclosed a vote on at least one PLIANT THERAPEUTICS INC. item in their SEC Form N-PX filings. Each item below shows how many of them voted on it, and how. Share totals are the shares those managers' funds voted, summed across every fund they report.

Elect Director: Darren Cline, MBA

Calculated outcomeDIRECTOR ELECTIONSPassed (calculated)

Combines 3 wordings of this item as funds reported it.

99.2% Majority: yes · of votes cast

FOR 99.2%
FOR: 51,397,449WITHHELD: 421,836
Details: description as filed, official tally, votes by 58 asset managers

Description as filed by funds: To elect three class III directors named in the proxy statement to our Board of Directors: Darren Cline, MBA

PLIANT THERAPEUTICS INC.’s own tally for this item (“Elect Director: Darren Cline, MBA”): 51,397,449 for, 421,836 withheld, per its Form 8-K filed June 14, 2024 (Item 5.07). FOR was more than half of the votes cast. Whether the item passed is for the filing to say; its statement has not been read for this item.

Outcome: Passed (calculated) — The company’s filing reports the vote counts but does not state the outcome; we calculated it from the counts: votes for exceeded votes against.
Support: 99.2% of votes cast — FOR ÷ (FOR + WITHHELD); abstentions and broker non-votes are excluded.

The 58 asset managers below reported 12,940,290 for, 248,223 withheld.

FOR
FOR: 12,940,290WITHHOLD: 248,223
Largest asset managers voting on “To elect three class III directors named in the proxy statement to our Board of Directors: Darren Cline, MBA” at PLIANT THERAPEUTICS INC., 2023-2024
Asset managerForAgainst AbstainWithheldVote
Vanguard3,337,9580 00For
T. Rowe Price2,805,4300 00For
BlackRock1,479,2780 00For
Capital Group1,377,3270 00For
Fidelity903,5420 00For
FRANKLIN STRATEGIC SERIES829,6000 00For
Charles Schwab430,8920 00For
Columbia Threadneedle310,3080 00For
Dimensional00 0183,701Withhold
Jackson National162,5230 01,526For
Victory Capital160,1270 00For
Equitable99,4890 058,180Mixed
TIAA146,2320 00For
State Street77,9270 00For
Lincoln Financial74,5160 02,509For
Russell Investments73,1060 00For
American Century63,6520 00For
WANGER ADVISORS TRUST58,4360 00For
Nushares ETF Trust55,8280 00For
ALGER FUNDS52,7230 00For
John Hancock48,2000 00For
QUANTITATIVE MASTER SERIES LLC44,2250 00For
AIG/SunAmerica31,4730 00For
Harbor Funds II30,6050 00For
Global X25,8680 00For

Showing the 25 largest of 58 asset managers. All 58 are in the interactive database (link above).

Elect Director: David Pyott, MA, MBA

Calculated outcomeDIRECTOR ELECTIONSPassed (calculated)

Combines 3 wordings of this item as funds reported it.

93% Majority: yes · of votes cast

FOR 93%
FOR: 48,388,729WITHHELD: 3,430,556
Details: description as filed, official tally, votes by 58 asset managers

Description as filed by funds: To elect three class III directors named in the proxy statement to our Board of Directors: David Pyott, MA, MBA

PLIANT THERAPEUTICS INC.’s own tally for this item (“Elect Director: David Pyott, MA, MBA”): 48,388,729 for, 3,430,556 withheld, per its Form 8-K filed June 14, 2024 (Item 5.07). FOR was more than half of the votes cast. Whether the item passed is for the filing to say; its statement has not been read for this item.

Outcome: Passed (calculated) — The company’s filing reports the vote counts but does not state the outcome; we calculated it from the counts: votes for exceeded votes against.
Support: 93% of votes cast — FOR ÷ (FOR + WITHHELD); abstentions and broker non-votes are excluded.

The 58 asset managers below reported 11,266,079 for, 1,922,434 withheld.

FORWITHHOLD
FOR: 11,266,079WITHHOLD: 1,922,434
Largest asset managers voting on “To elect three class III directors named in the proxy statement to our Board of Directors: David Pyott, MA, MB” at PLIANT THERAPEUTICS INC., 2023-2024
Asset managerForAgainst AbstainWithheldVote
Vanguard3,337,9580 00For
T. Rowe Price2,805,4300 00For
BlackRock00 01,479,278Withhold
Capital Group1,377,3270 00For
Fidelity881,0980 022,444For
FRANKLIN STRATEGIC SERIES829,6000 00For
Charles Schwab430,8920 00For
Columbia Threadneedle310,3080 00For
Dimensional00 0183,701Withhold
Jackson National162,5230 01,526For
Victory Capital160,1270 00For
Equitable10,5200 0147,149Mixed
TIAA146,2320 00For
State Street77,9270 00For
Lincoln Financial74,5160 02,509For
Russell Investments73,1060 00For
American Century63,6520 00For
WANGER ADVISORS TRUST58,4360 00For
Nushares ETF Trust55,8280 00For
ALGER FUNDS52,7230 00For
John Hancock48,2000 00For
QUANTITATIVE MASTER SERIES LLC00 044,225Withhold
AIG/SunAmerica31,4730 00For
Harbor Funds II30,6050 00For
Global X25,8680 00For

Showing the 25 largest of 58 asset managers. All 58 are in the interactive database (link above).

Elect Director: Hoyoung Huh, M.D., Ph.D.

Calculated outcomeDIRECTOR ELECTIONSPassed (calculated)

Combines 3 wordings of this item as funds reported it.

75% Majority: yes · of votes cast

FOR 75%WITHHELD
FOR: 39,087,800WITHHELD: 12,731,485
Details: description as filed, official tally, votes by 58 asset managers

Description as filed by funds: To elect three class III directors named in the proxy statement to our Board of Directors: Hoyoung Huh, M.D., Ph.D.

PLIANT THERAPEUTICS INC.’s own tally for this item (“Elect Director: Hoyoung Huh, M.D., Ph.D.”): 39,087,800 for, 12,731,485 withheld, per its Form 8-K filed June 14, 2024 (Item 5.07). FOR was more than half of the votes cast. Whether the item passed is for the filing to say; its statement has not been read for this item.

Outcome: Passed (calculated) — The company’s filing reports the vote counts but does not state the outcome; we calculated it from the counts: votes for exceeded votes against.
Support: 75% of votes cast — FOR ÷ (FOR + WITHHELD); abstentions and broker non-votes are excluded.

The 58 asset managers below reported 12,257,179 for, 931,334 withheld.

FOR
FOR: 12,257,179WITHHOLD: 931,334
Largest asset managers voting on “To elect three class III directors named in the proxy statement to our Board of Directors: Hoyoung Huh, M.D., ” at PLIANT THERAPEUTICS INC., 2023-2024
Asset managerForAgainst AbstainWithheldVote
Vanguard3,337,9580 00For
T. Rowe Price2,805,4300 00For
BlackRock1,479,2780 00For
Capital Group1,377,3270 00For
Fidelity903,5420 00For
FRANKLIN STRATEGIC SERIES829,6000 00For
Charles Schwab430,8920 00For
Columbia Threadneedle310,3080 00For
Dimensional00 0183,701Withhold
Jackson National00 0164,049Withhold
Victory Capital00 0160,127Withhold
Equitable99,4890 058,180Mixed
TIAA146,2320 00For
State Street77,8160 0111For
Lincoln Financial47,3000 029,725Mixed
Russell Investments73,1060 00For
American Century00 063,652Withhold
WANGER ADVISORS TRUST58,4360 00For
Nushares ETF Trust55,8280 00For
ALGER FUNDS00 052,723Withhold
John Hancock27,0820 021,118Mixed
QUANTITATIVE MASTER SERIES LLC44,2250 00For
AIG/SunAmerica00 031,473Withhold
Harbor Funds II30,6050 00For
Global X25,8680 00For

Showing the 25 largest of 58 asset managers. All 58 are in the interactive database (link above).

Company's stockholders failed to approve, on a non-binding advisory basis, the compensation of the Company's named…

Calculated outcomeFund totals may overlapSECTION 14A SAY-ON-PAY VOTESFailed (calculated)

Combines 6 wordings of this item as funds reported it.

45.3% Majority: no · of votes cast

FOR 45.3%AGAINST
FOR: 23,479,353AGAINST: 28,329,655

Prior year: 97.2% for (June 7, 2023 meeting) ▼ 51.9 pts

Details: description as filed, official tally, votes by 175 asset managers

Description as filed by funds: TO APPROVE, BY NON-BINDING ADVISORY VOTE, THE RESOLUTION APPROVING NAMED EXECUTIVE OFFICER COMPENSATION.

PLIANT THERAPEUTICS INC.’s own tally for this item (“2. The Company's stockholders failed to approve, on a non-binding advisory basis, the compensation of the Company's named executive officers”): 23,479,353 for, 28,329,655 against, per its Form 8-K filed June 14, 2024 (Item 5.07). FOR was not more than half of the votes cast. Whether the item passed is for the filing to say; its statement has not been read for this item.

Outcome: Failed (calculated) — The company’s filing reports the vote counts but does not state the outcome; we calculated it from the counts using a majority of the votes cast, the standard stated in the company’s 8-K: votes for did not exceed votes against.
Support: 45.3% of votes cast — FOR ÷ (FOR + AGAINST); abstentions and broker non-votes are excluded.
Voting standard, as the filing states it: a majority of the votes cast (“majority of the votes cast”).

Fund voting reports and institutional-manager reports both cover this item. An institutional manager can report shares that a fund it advises also reports, so the two are shown separately below and never added together, and their sum is not shown (fund and manager reports combined may count the same shares twice).

Fund voting reports: 58 asset managers voting on “TO APPROVE, BY NON-BINDING ADVISORY VOTE, THE RESOLUTION APPROVING NAMED EXECUTIVE OFFICER COMPENSATION.” at PLIANT THERAPEUTICS INC., 2023-2024
Asset managerForAgainst AbstainWithheldVote
Vanguard3,337,9580 00For
T. Rowe Price02,805,430 00Against
BlackRock01,479,278 00Against
Capital Group01,377,327 00Against
Fidelity307,321596,221 00Mixed
FRANKLIN STRATEGIC SERIES0829,600 00Against
Charles Schwab0430,892 00Against
Columbia Threadneedle0310,308 00Against
Dimensional0183,701 00Against
Jackson National0164,049 00Against
Victory Capital0160,127 00Against
Equitable0157,669 00Against
TIAA0146,232 00Against
State Street77,816111 00For
Lincoln Financial47,30029,725 00Mixed
Russell Investments073,106 00Against
American Century063,652 00Against
WANGER ADVISORS TRUST058,436 00Against
Nushares ETF Trust055,828 00Against
ALGER FUNDS052,723 00Against
John Hancock048,200 00Against
QUANTITATIVE MASTER SERIES LLC044,225 00Against
AIG/SunAmerica031,473 00Against
Harbor Funds II30,6050 00For
Global X025,868 00Against

Fund voting reports, all 58 managers: 3,805,035 for, 9,383,478 against. Showing the 25 largest; every one is in the interactive database (link above).

Institutional-manager reports: 135 asset managers voting on “TO APPROVE, BY NON-BINDING ADVISORY VOTE, THE RESOLUTION APPROVING NAMED EXECUTIVE OFFICER COMPENSATION.” at PLIANT THERAPEUTICS INC., 2023-2024
Asset managerForAgainst AbstainWithheldVote
Deep Track Capital, LP4,415,3430 00For
T. Rowe Price03,571,448 00Against
Redmile Group, LLC03,499,816 00Against
Laurion Capital Management LP03,474,744 00Against
First Light Asset Management, LLC3,276,9450 00For
TRV GP IV, LLC2,132,8670 00For
Fidelity2,077,2880 00For
Polar Capital Holdings Plc01,989,220 00Against
GREAT POINT PARTNERS LLC1,725,9360 00For
FRANKLIN ADVISERS INC01,513,287 00Against
Capital Group41,377,327 00Against
BlackRock20,1141,229,197 00Against
PICTET ASSET MANAGEMENT SA01,189,593 00Against
State Street1,047,58716,864 00For
BESSEMER TRUST Co NATIONAL ASSOCIATION01,059,388 00Against
RA CAPITAL MANAGEMENT, L.P.995,2860 00For
Granahan Investment Management, LLC0686,064 00Against
Citadel647,3000 00For
GEODE CAPITAL MANAGEMENT, LLC0646,434 00Against
Candriam S.C.A.0548,000 00Against
Bessemer Trust CO of Delaware, N.A.0541,619 00Against
BESSEMER TRUST CO0532,079 00Against
BESSEMER TRUST Co OF FLORIDA0532,079 00Against
Bessemer Trust Co of California, N.A.0532,079 00Against
Bessemer Trust Co of Nevada, National Association0532,079 00Against

Institutional-manager reports, all 135 managers: 17,465,443 for, 26,004,033 against, 4,535 not voted. Showing the 25 largest; every one is in the interactive database (link above).

The selection of Deloitte & Touche LLP as the Company's independent registered public accounting firm

Official resultAUDIT-RELATEDReported outcome: Approved

Combines 3 wordings of this item as funds reported it.

99.9% Approved · of votes cast

FOR 99.9%
FOR: 56,628,368AGAINST: 10,853

Prior year: 100.0% for (June 7, 2023 meeting) unchanged

Details: description as filed, official tally, votes by 58 asset managers

Description as filed by funds: To ratify the appointment of Deloitte & Touche LLP as our independent registered public accounting firm for the fiscal year ending December 31, 2023.

PLIANT THERAPEUTICS INC.’s own tally for this item (“3. The selection of Deloitte & Touche LLP as the Company's independent registered public accounting firm”): 56,628,368 for, 10,853 against — passed, per its Form 8-K filed June 14, 2024 (Item 5.07).

Reported outcome: Approved, in the filing’s own words: “Proposal 3: The Company's stockholders ratified the selection of Deloitte & Touche LLP as the Company's independent registered public accounting firm.”
Support: 99.9% of votes cast — FOR ÷ (FOR + AGAINST); abstentions and broker non-votes are excluded.

The 58 asset managers below reported 13,188,513 for.

FOR
FOR: 13,188,513
Largest asset managers voting on “To ratify the appointment of Deloitte & Touche LLP as our independent registered public accounting firm for th” at PLIANT THERAPEUTICS INC., 2023-2024
Asset managerForAgainst AbstainWithheldVote
Vanguard3,337,9580 00For
T. Rowe Price2,805,4300 00For
BlackRock1,479,2780 00For
Capital Group1,377,3270 00For
Fidelity903,5420 00For
FRANKLIN STRATEGIC SERIES829,6000 00For
Charles Schwab430,8920 00For
Columbia Threadneedle310,3080 00For
Dimensional183,7010 00For
Jackson National164,0490 00For
Victory Capital160,1270 00For
Equitable157,6690 00For
TIAA146,2320 00For
State Street77,9270 00For
Lincoln Financial77,0250 00For
Russell Investments73,1060 00For
American Century63,6520 00For
WANGER ADVISORS TRUST58,4360 00For
Nushares ETF Trust55,8280 00For
ALGER FUNDS52,7230 00For
John Hancock48,2000 00For
QUANTITATIVE MASTER SERIES LLC44,2250 00For
AIG/SunAmerica31,4730 00For
Harbor Funds II30,6050 00For
Global X25,8680 00For

Showing the 25 largest of 58 asset managers. All 58 are in the interactive database (link above).

Largest PLIANT THERAPEUTICS INC. shareholders voting in 2023-2024

Ranked separately for each type of Form N-PX report. An institutional manager can report shares that a fund it advises also reports, so the two tables can list the same shares and are never added together. Each is ranked by the shares voted on the item that the most managers of that type reported, shown as a share of the 60,325,832 shares outstanding at the time of that meeting.

Fund voting reports: top PLIANT THERAPEUTICS INC. shareholders by shares voted on “TO APPROVE, BY NON-BINDING ADVISORY VOTE, THE RESOLUTION APPROVING NAMED EXECUTIVE OFFICER…”, 2023-2024
#Asset manager % of shares outstanding
1Vanguard 5.53%
2T. Rowe Price 4.65%
3BlackRock 2.45%
4Capital Group 2.28%
5Fidelity 1.50%
6FRANKLIN STRATEGIC SERIES 1.38%
7Charles Schwab 0.71%
8Columbia Threadneedle 0.51%
9Dimensional 0.30%
10Jackson National 0.27%
Institutional-manager reports: top PLIANT THERAPEUTICS INC. shareholders by shares voted on “TO APPROVE, BY NON-BINDING ADVISORY VOTE, THE RESOLUTION APPROVING NAMED EXECUTIVE OFFICER…”, 2023-2024
#Asset manager % of shares outstanding
1Deep Track Capital, LP 7.32%
2T. Rowe Price 5.92%
3Redmile Group, LLC 5.80%
4Laurion Capital Management LP 5.76%
5First Light Asset Management, LLC 5.43%
6TRV GP IV, LLC 3.54%
7Fidelity 3.44%
8Polar Capital Holdings Plc 3.30%
9GREAT POINT PARTNERS LLC 2.86%
10FRANKLIN ADVISERS INC 2.51%

Reported PLIANT THERAPEUTICS INC. holdings and ownership

As disclosed to the SEC in Form 13F (quarter-end holdings of 30 large managers), Schedules 13D and 13G (beneficial ownership above 5%) and the company’s own proxy statement (DEF 14A). Each row gives its source and the date its figure is as of: for Form 13F the quarter end it reports, for Schedules 13D and 13G the filing date, and for the proxy statement the date of its ownership table (or, where that date has not been read, the date the proxy was filed). The rows are therefore not all as of the same day.

PLIANT THERAPEUTICS INC. holdings and ownership disclosed for the 2023-2024 proxy season, with each row’s source and date
HolderShares % outstandingSource, as of
Deep Track Capital, LP5,750,000 9.53%Proxy statement (DEF 14A), proxy filed April 22, 2024
FMR LLC3,963,417 6.57%Proxy statement (DEF 14A), proxy filed April 22, 2024
T. Rowe Price3,959,088 6.56%Form 13F, quarter ended March 31, 2024
First Light Asset Management LLC3,634,510 6.02%Proxy statement (DEF 14A), proxy filed April 22, 2024
S F3,634,510 6.02%Schedule 13G, filed February 14, 2024
Laurion Capital Management LP3,583,567 5.94%Proxy statement (DEF 14A), proxy filed April 22, 2024
Morgan Stanley3,507,288 5.81%Form 13F, quarter ended March 31, 2024
Blue Owl Capital Holdings L.P.3,004,199 4.98%Proxy statement (DEF 14A), proxy filed April 22, 2024
Vanguard Group2,775,938 4.60%Form 13F, quarter ended March 31, 2024
JPMorgan Chase2,130,489 3.53%Form 13F, quarter ended March 31, 2024

Percentages above are of 60,325,832 shares outstanding, as reported by PLIANT THERAPEUTICS INC. on its Form 10-Q dated May 1, 2024 (see the filing on EDGAR). This is the count contemporaneous with the 2023-2024 meeting, not today’s. Each holding is as of its own filing, which may be dated before or after the meeting.

About this meeting

At PLIANT THERAPEUTICS INC.'s shareholder meeting held June 13, 2024, in the 2023-2024 proxy season, 175 asset managers reported votes on at least one of its 5 ballot items in their SEC Form N-PX filings, covering 996 separate fund positions. On the most widely held item on that ballot — TO APPROVE, BY NON-BINDING ADVISORY VOTE, THE RESOLUTION APPROVING NAMED EXECUTIVE OFFICER… — FOR was 45.3% of the votes cast (FOR divided by FOR plus AGAINST, the conventional basis for proxy support; abstentions, broker non-votes and unvoted shares are excluded because none of them took a side), which is not more than half. Whether the item was approved is for the filing to say; that statement has not been read for this item. Source: PLIANT THERAPEUTICS INC.'s Form 8-K, Item 5.07, filed with the U.S. Securities and Exchange Commission on June 14, 2024.

Related

About this page

Every figure above is derived from filings made with the US Securities and Exchange Commission: Form N-PX, in which registered funds disclose how they voted every proxy and institutional managers disclose their votes on executive pay (say-on-pay, say-on-frequency and golden parachutes), and Form 8-K Item 5.07, in which the company reports its own meeting results. Shares outstanding are taken from PLIANT THERAPEUTICS INC.’s 10-Q dated May 1, 2024. This page is a static snapshot rebuilt weekly on November 20, 2026; a live search always shows the current data.

PLIANT THERAPEUTICS INC. proxy season coverage: 2023-2024 (this page) · 2024-2025 · 2025-2026.

Cite this page

Proxy Votes Now, “PLIANT THERAPEUTICS (PLRX) 2024 Annual Meeting: Vote Results”, https://proxyvotesnow.com/company/pliant-therapeutics-inc/2024 (version of November 20, 2026). Derived from SEC Form N-PX and Form 8-K filings; tables licensed CC BY 4.0. Licence: CC BY 4.0.